Jefferies lowered the firm’s price target on Centene (CNC) to $61 from $64 and keeps a Hold rating on the shares. Centene “printed the most encouraging 1Q HIX results among its peers,” says the analyst in reference to the Health Insurance Exchange business. However, management flagged core utilization pressures and “meaningful effort is required to preserve the EPS guide,” the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene’s Strategic Growth and Stability Justify Buy Rating Despite Price Target Adjustment
- Centene price target lowered to $65 from $72.50 at BofA
- Centene price target lowered to $84 from $93 at Barclays
- Centene Corporation Reports Strong Q1 2025 Results
- Centene’s Earnings Call: Growth Amid Challenges